In a concerted legal manoeuvre, a coalition of twenty-seven states and the District of Columbia have initiated proceedings against 23andMe, the prominent purveyor of consumer genetic assays, seeking injunctive relief to forestall the potential divestiture of granular personal genomic data absent explicit, informed consent from each data subject, precipitated by a proposed acquisition by a biotechnology entity of the financially beleaguered genomics firm; Oregon Attorney General Dan Rayfield, in a formal communiqué, posited that the totality of sensitive information—encompassing biological specimens, de-identified DNA sequences, phenotypic predispositions, and longitudinal medical dossiers—cannot be commoditised without the unequivocal, affirmative authorisation of each individual, as 23andMe, since its inception in 2006, has proferred direct-to-consumer, saliva-based DNA analyses facilitating ancestral investigations and familial consanguinity ascertainment, yet has grappled with establishing a sustainable revenue architecture post-initial public offering in 2021, culminating in a significant workforce reduction of forty percent and the invocation of Chapter 11 bankruptcy protection in March, while Regeneron Pharmaceuticals, the prospective acquirer for a sum of $256 million, has avowed adherence to extant 23andMe privacy protocols and relevant statutory mandates, with an independent consumer privacy ombudsman charged with conducting a comprehensive review of the proposed transaction and its prospective ramifications for consumer data protection.